Physician profile
Mark R Kaiser
NPI 1710171335
$2,132.88
in general payments reported to CMS, 2019-2025
21 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $163 · 2021: $359 · 2022: $434 · 2023: $301 · 2024: $375 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $464.38 | 2019-2024 | Tremfya, Stelara, Remicade |
| Regeneron Healthcare Solutions, INC. | $306.45 | 2019-2025 | Libtayo, Dupixent |
| Abbvie INC. | $294.71 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $186.44 | 2020-2025 | Blu-U, Odomzo |
| Leo Pharma INC. | $157.46 | 2019-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $143.21 | 2022-2025 | |
| Pfizer INC. | $112.33 | 2019-2023 | |
| Helsinn Therapeutics (U.S.), INC. | $74.93 | 2021-2023 | Valchlor |
| Incyte Corporation | $74.51 | 2022-2023 | Opzelura |
| Lilly USA, LLC | $53.23 | 2019-2024 | Taltz, Ebglyss |
| Sensus Healthcare, INC. | $49.70 | 2019 | |
| Dermavant Sciences, INC. | $44.65 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $32.81 | 2021-2025 | Nemluvio |
| Organon LLC | $30.54 | 2025 | Vtama |
| Kerecis Limited | $22.41 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.81 | 2022 | |
| Mimedx Group, INC. | $15.32 | 2025 | |
| Genzyme Corporation | $15.22 | 2019 | |
| Biofrontera INC. | $13.52 | 2022 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 | |
| Strata Skin Sciences, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kaiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.